Penpulimab (Penpulimab-kcqx)

Penpulimab (penpulimab-kcqx) is a programmed death receptor-1 (PD-1)-blocking antibody used:

• in combination with medicine, either cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC).
• as a single agent for the treatment of adults with metastatic non-keratinizing NPC with disease progression on or after platinum-based chemotherapy and at least 1 other prior line of therapy.

Recommended Dosage:

• Recommended Dosage of Penpulimab-kcqx in Combination with Either Cisplatin or Carboplatin and Gemcitabine: The recommended dosage of penpulimab-kcqx as a First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma is 200 mg administered as an intravenous (IV) infusion over 60 minutes every 3 weeks until there is evidence of disease progression or unacceptable toxicity, for a maximum of 24 months.
• Recommended Dosage of Penpulimab-kcqx as a Single Agent: The recommended dosage of penpulimab-kcqx for Recurrent Metastatic Non-Keratinizing Nasopharyngeal Carcinoma is 200 mg administered as an intravenous (IV) infusion over 60 minutes every 2 weeks until there is evidence of disease progression or unacceptable toxicity, for a maximum of 24 months.

• Penpulimab-kcqx might cause serious, possibly life-threatening, immune-related complications involving the lungs, liver, intestines, and various other systems. Patients having any strange signs or symptoms during the course of treatment need to be proactive in order to avoid medical complications.
• This drug carries both pre- and post-infusion complications, which consist of chills, fever, rash around the IV site, or shortness of breath. Healthcare professionals should monitor patients closely throughout the treatment and be ready to halt or manage the reaction if signs and symptoms become severe.
• Allogeneic HSCT with the use of this medicine poses extreme risks, such as complications in graft–versus–host disease, which can be fatal. A deep analysis of the merits against the demerits needs to be taken before proceeding with HSCT post-treatment using this immunotherapy medicine.
• Both males and females who are of reproductive age should exercise reproductive restriction during the period of treatment or several months post-treatment, along with the last dose, in order to mitigate the risks of a harmful fetus formation and to enable safe family planning initiatives during the treatment period.
• Using Penpulimab-kcqx 100 mg/10 mL injection during the pregnancy period may pose risks of harming the baby, and opt not to use this medicine. Talk to your healthcare provider (HCP) about any risks before undergoing treatment during pregnancy.
• It is not yet known whether Penpulimab-kcqx passes into breast milk. To mitigate the risks to the child, women are advised not to breastfeed during this period based on the doctor's directions.
• Currently, there is no established safety and efficacy of Penpulimab-kcqx in children. The drug is not to be used on pediatric patients unless absolutely necessary, and in such a clear need, a healthcare provider should justify the need while closely monitoring the child.
• There isn't enough information regarding Penpulimab-kcqx and elderly patients aged 65 and above. Despite no differences in safety being noted, older patients might be more vulnerable. Ranger-based physicians should keep a close eye on any elderly patients for possible adverse effects or complications.

What documents are required to import PENPULIMAB to India?

PENPULIMAB (penpulimab-kcqx) injections can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is PENPULIMAB available in India?

PENPULIMAB (penpulimab-kcqx injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On availability of Penpulimab in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

PENPULIMAB can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of PENPULIMAB (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Penpulimab 100 mg/10 mL injection price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source PENPULIMAB (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

What is the Generic Name for the trade name drug Penpulimab®?

Penpulimab-kcqx is a Generic Name for the trade name drug Penpulimab®.

What is the Manufacturer's Name of Penpulimab®?

Penpulimab® is jointly manufactured by two companies, Akeso, Inc., and Chia Tai Tianqing.

Is Penpulimab approved by the FDA?

Yes, Penpulimab® is approved by the FDA. Date of first approval: April 23, 2025.

What is the dosage and form of Penpulimab® supplied?

Penpulimab is supplied for Injection: 100 mg/10 mL (10 mg/mL) solution in a single-dose vial for intravenous (IV) use.

What are the most common side effects of Penpulimab® 100 mg/10 mL injections?

The most common side effects of Penpulimab® injection are fatigue, decreased weight, cough, COVID-19 infection, rash, hypothyroidism, nausea, vomiting, constipation, pyrexia, decreased appetite, anemia, and hypothyroidism.

How much does Penpulimab® 100 mg/10 mL injection cost in India?

Prices of Penpulimab injections may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Penpulimab 100 mg/10 mL cost in India, please call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Penpulimab® 100 mg/10 mL injections be available in SAARC countries?

Apart from Gulf countries, Penpulimab® can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Penpulimab® injections in these countries. We help ensure legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Penpulimab® 100 mg/10 mL injections online in India?

Yes, one can buy Penpulimab 100 mg/10 mL online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the legal supply of Penpulimab® injections through legal channels.

What are the storage conditions of Penpulimab® 100 mg/10 mL injections?

Store refrigerated at 2-8°C (36-46°F) in the original carton to protect from light. Neither shake nor freeze it.